Conferences

BIO-Europe 2010: Scientia Advisors to Participate in a Panel on The Future of Diagnostics' Partnering Strategy

Topic:

The Future of Diagnostics' Partnering Strategy
Much has been said regarding the evolving role biomarkers and companion diagnostics have within drug development and therapeutic treatment. One aspect that is still to be examined is how personalized medicine and companion diagnostics will be integrated within comparative effectiveness research (CER), especially as European regulatory bodies seem to be embracing CER as the most efficient means to determine the best treatment for patients. As this situation evolves, how will diagnostic companies and their pharma partners be affected by this new regulatory atmosphere? How will the increasing demands for CER change the roles that regulators and payors have traditionally had in the drug development model and how will it affect the treatment that is ultimately provided for patients?

Panelist well versed in the current transitioning environment of the life sciences industry will discuss how biotech and diagnostics companies can adapt to these new demands.

Panelists:

Harry Glorikian, Founder and Managing partner, Scientia Advisors
Peter Homberg, Partner, Raupach & Wollert-Elmendorff
Ruediger Weseloh, Senior Director, Head Negotiations, Merck Serono S.A. Geneva
Arshad Ahmed, Founding Partner, Scientia Advisors

More information at: BIO-Europe 2010, Biotechnology Partnering Conference

EVENT INFORMATION »

Date:
Nov 15, 2010

Time:
4:00PM to 5:00PM

Location:
International Congress Center Munich (ICM), Munich, Germany

Hosted by:
EBD Group

Registration Information:
Register now »

SCIENTIA ADVISORS, LLC | info@scientiaadv.com

55 Cambridge Parkway, Suite 300E, Cambridge MA 02142 | Phone: 617-299-3000 | Fax: 617-812-0315